Cervical cancer vaccines from Merck and GlaxoSmithKline could be cost-effective if subsidies or new prices are created so developing countries can afford them, researchers said Thursday at the World Cancer Congress in Geneva, Reuters reports.
Cervical cancer vaccines could be cost-effective for developing countries, researchers say